GANX
Gain Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.25
−0.79%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.13
- Revenue estimate
- $33.3K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.14
- Revenue actual
- —
- Revenue estimate
- $33.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +10.4%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.50
- PT range
- $5.00 – $8.00
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.14 | -$0.11 | Beat 20.29% | — |
| May 11, 2026 | -$0.13 | -$0.13 | In line | — |
| Mar 26, 2026 | -$0.14 | -$0.11 | Beat 21.43% | — |
| Nov 12, 2025 | -$0.15 | -$0.15 | In line | — |
| Aug 12, 2025 | -$0.17 | -$0.19 | Miss -11.76% | — |
| May 14, 2025 | -$0.16 | -$0.16 | In line | — |
| Mar 27, 2025 | -$0.18 | -$0.11 | Beat 38.89% | — |
| Nov 14, 2024 | -$0.23 | -$0.17 | Beat 26.09% | — |
| Aug 8, 2024 | -$0.31 | -$0.42 | Miss -35.48% | — |
| Nov 14, 2023 | -$0.47 | -$0.37 | Beat 21.28% | — |
| Aug 10, 2023 | -$0.33 | -$0.62 | Miss -87.88% | — |
| May 12, 2023 | -$0.40 | -$0.43 | Miss -7.50% | $55.2K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026